

IVI and the Ministry of Foreign Affairs of Ecuador exchange MOU to pursue global health research & development

SEOUL, REPUBLIC OF KOREA, November 25, 2020 / EINPresswire.com/ -- The International Vaccine Institute (IVI) and the Ministry of Foreign Affairs and Human Mobility of Ecuador exchanged a memorandum of understanding (MOU) yesterday at IVI headquarters in Seoul, Republic of Korea to explore areas of collaboration in infectious disease research, epidemiology, and vaccine R&D.

Dr. Jerome Kim, Director General of IVI, and His Excellency Luis Gallegos, Minister of Foreign Affairs of the Republic of Ecuador, signed the MOU during a bilateral meeting while the Minister makes his official visit to Korea.



His Excellency Luis Gallegos, Minister of Foreign Affairs of the Republic of Ecuador (left), and Dr. Jerome Kim, Director General of IVI (right) signed a memorandum of understanding at IVI headquarters on November 24, 2020 to explore areas of collaboratio

"We're pleased to pursue greater opportunities with Ecuador, an early supporter of IVI and state party to the organization's establishment treaty, to advance vaccine science and strengthen pandemic preparedness," said Dr. Kim. "The COVID-19 pandemic has made clear the critical importance of global cooperation in vaccine research, development, and delivery, and IVI welcomes closer bi- and multilateral partnerships."

###

About the International Vaccine Institute (IVI) The International Vaccine Institute (IVI) is a nonprofit inter-governmental organization established in 1997 at the initiative of the United Nations Development Programme (UNDP). Headquartered in Seoul, South Korea, IVI was the first international organization hosted by Korea. IVI has 36 signatory countries and the World Health Organization (WHO) on its treaty, including Korea, Sweden, India, and Finland as state funders.

Our mandate is to make vaccines available and accessible for the world's most vulnerable people. We focus on infectious diseases of global health importance such as cholera, typhoid, shigella, salmonella, schistosomiasis, Group A Strep, Hepatitis A, HPV, TB, HIV, MERS, COVID-19, as well as antimicrobial resistance. For more information, please visit <u>https://www.ivi.int</u>

Aerie Em International Vaccine Institute +82 2-881-1386 aerie.em@ivi.int Visit us on social media: Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/531474292

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2021 IPD Group, Inc. All Right Reserved.